<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>U.S.</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>D&amp;D’s zabopegdutide shows more upbeat top-line phase II MASH data </title>
      <description>
        <![CDATA[D&D Pharmatech Inc. announced May 27 positive top-line tissue biopsy results of zabopegdutide (DD-01) from a 48-week phase II study of metabolic dysfunction-associated steatohepatitis (MASH), pushing company shares up 30% on the day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731650</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731650-d-and-ds-zabopegdutide-shows-more-upbeat-top-line-phase-ii-mash-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-damage-fibrosis-cirrhosis.webp?t=1769528466" type="image/jpeg" medium="image" fileSize="677639">
        <media:title type="plain">Art concept for liver damage, such as fatty liver, fibrosis or cirrhosis</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS-Hengrui deal strikes panic in Washington</title>
      <description>
        <![CDATA[On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731649</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731649-bms-hengrui-deal-strikes-panic-in-washington</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>China launches long-awaited drug data protection rules </title>
      <description>
        <![CDATA[China’s National Medical Products Administration has issued final implementation measures for drug trial data protection that mark a significant step toward aligning China’s pharmaceutical intellectual property framework with global standards.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731647</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731647-china-launches-long-awaited-drug-data-protection-rules</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cybersecurity-data-lock.webp?t=1588286982" type="image/png" medium="image" fileSize="321597">
        <media:title type="plain">Cybersecurity data lock</media:title>
      </media:content>
    </item>
    <item>
      <title>Hanmi, Haisco win billion-dollar partnerships with Eli Lilly</title>
      <description>
        <![CDATA[Hanmi Pharmaceutical Co. Ltd. secured a $1.26 billion deal with Eli Lilly and Co. to out-license ex-Korea rights to sonefpeglutide (HM-15912), a Lapscovery-based glucagon-like peptide-2 analog in development for multiple indications, including an ongoing phase II study of short bowel syndrome. It was one of two billion-dollar Asian company deals signed by Lilly on June 1, with the second transaction involving Haisco Pharmaceutical Group Co. Ltd., of Beijing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731645</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731645-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Hanmi-signage-6-1.webp?t=1780342948" type="image/jpeg" medium="image" fileSize="195343">
        <media:title type="plain">Hanmi signage</media:title>
        <media:description type="plain">Credit: Hanmi Pharmaceutical Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal</title>
      <description>
        <![CDATA[Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731644</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731644-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Antibodies-attacking-cancer-cell.webp?t=1621365766" type="image/png" medium="image" fileSize="566115">
        <media:title type="plain">Antibodies attacking cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Fulcrum drops work on SCD drug pociredir; stock plummets</title>
      <description>
        <![CDATA[Shares of Fulcrum Therapeutics Inc. (NASDAQ:FULC) fell 54% after the company said it is discontinuing work on sickle cell disease (SCD) candidate pociredir, its only clinical-stage candidate, and reviewing strategic alternatives in the wake of the U.S. FDA’s safety concerns regarding the drug target.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731532</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731532-fulcrum-drops-work-on-scd-drug-pociredir-stock-plummets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Sickle-cell-pic.webp?t=1589217567" type="image/png" medium="image" fileSize="558183">
        <media:title type="plain">Sickle cell illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears Shionogi’s Xocova as first COVID-19 prevention pill</title>
      <description>
        <![CDATA[The U.S. FDA approved Shionogi & Co. Ltd.’s Xocova (ensitrelvir) as the first oral post-exposure prophylactic option in the U.S. to prevent COVID-19, with the decision coming ahead of a PDUFA target date of June 16.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731531</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731531-fda-clears-shionogis-xocova-as-first-covid-19-prevention-pill</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Xocova-blister-pack.webp?t=1780425132" type="image/jpeg" medium="image" fileSize="147892">
        <media:title type="plain">Xocova blister pack</media:title>
        <media:description type="plain">Credit: Shionogi &amp;amp; Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA advises leveraging what’s already known in gene therapy R&amp;D</title>
      <description>
        <![CDATA[Rather than reinventing the wheel for every gene therapy that uses genome editing, the U.S. FDA is advising sponsors on leveraging existing knowledge, be it publicly available or platform-based, to more efficiently advance their products across multiple stages of development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731529</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731529-fda-advises-leveraging-whats-already-known-in-gene-therapy-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-gene-editing.webp?t=1730128296" type="image/jpeg" medium="image" fileSize="222415">
        <media:title type="plain">DNA double helix illustration with section being removed in red</media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: Celcuity’s positive phase III gets no love from investors</title>
      <description>
        <![CDATA[Minneapolis-based Celcuity Inc. was like the Rolling Stones at the 2026 American Society of Clinical Oncology annual meeting. The company reported positive phase III data for its pan-PI3K/mTORC1/2 inhibitor gedatolisib, but Celcuity (NASDAQ:CELC) couldn’t get any satisfaction from investors who sent shares down 25.7%, or $31.54, to $91.42 on June 2, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731527</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731527-asco-2026-celcuitys-positive-phase-iii-gets-no-love-from-investors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Dec-2020/Science-breast-cancer-cell-12-9.webp?t=1607542510" type="image/png" medium="image" fileSize="570840">
        <media:title type="plain">Breast cancer cell</media:title>
        <media:description type="plain">Breast cancer cell. Credit: Bruce Wetzel and Harry Schaefer, NCI</media:description>
      </media:content>
    </item>
    <item>
      <title>Travere expands rare kidney portfolio in $1B+ Everest deal </title>
      <description>
        <![CDATA[Less than two months after winning FDA approval for a second indication for Filspari (sparsentan), Travere Therapeutics Inc. added to its rare kidney disease pipeline by exclusively licensing civorebrutinib from Everest Medicines Ltd. in a deal that could be worth more than $1.14 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731526</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731526-travere-expands-rare-kidney-portfolio-in-1b-everest-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/Nephrology-Renal-Kidney.webp?t=1669825127" type="image/png" medium="image" fileSize="946164">
        <media:title type="plain">3D illustration of kidney cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>Cancer specter looming, Abtect effect in UC wallops Abivax</title>
      <description>
        <![CDATA[Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up in phase III top-line data from the Abtect maintenance trial with obefazimod. Paris-based Abivax SA’s oral, first-in-class miRNA-124 enhancer performed well in adults with moderately to severely active ulcerative colitis (UC), but shares of (NASDAQ:ABVX) closed June 2 at $72.50, down 44%, or $57.19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731525</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731525-cancer-specter-looming-abtect-effect-in-uc-wallops-abivax</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Stomach-pain.webp?t=1745258577" type="image/jpeg" medium="image" fileSize="208753">
        <media:title type="plain">Person holding stomach in pain </media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: Drugmakers go ‘WEE1’ for early data </title>
      <description>
        <![CDATA[At the 2026 American Society of Clinical Oncology annual meeting, multiple companies presented data for their drugs targeting WEE1, a checkpoint for the transition from G2 into mitosis. Aprea Therapeutics Inc. presented phase 1 data for its WEE1 inhibitor APR-1051 in patients with advanced solid tumors showing two patients with endometrial cancers achieved partial responses in the dose-escalation study. Likewise, Zentalis Pharmaceuticals Inc. had tantalizing early results from a phase Ib study showing azenosertib plus paclitaxel in patients with platinum-resistant ovarian cancer produced an overall response rate of 39% with a median progression-free survival of 7.3 months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731509</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731509-asco-2026-drugmakers-go-wee1-for-early-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/cancer-dna-diagnostic.webp?t=1682529493" type="image/png" medium="image" fileSize="705763">
        <media:title type="plain">Cancer cell, DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: A revolution in pancreatic cancer </title>
      <description>
        <![CDATA[At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the phase III RASolute 302 study of its pan-RAS inhibitor daraxonrasib in patients with previously treated, metastatic pancreatic ductal adenocarcinoma. The results were simultaneously published in <em>The New England Journal of Medicine</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731516</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731516-asco-2026-a-revolution-in-pancreatic-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas-3D-hologram.webp?t=1780342546" type="image/jpeg" medium="image" fileSize="208024">
        <media:title type="plain">Pancreas 3D hologram</media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: Grail shifts focus to secondary endpoints in UK study</title>
      <description>
        <![CDATA[New data from Grail Inc.’s randomized study of its Galleri multicancer early detection test could not alter the fact that the U.K. trial missed the primary endpoint of reducing the number of cancers diagnosed at stage III and stage IV. But the company is now suggesting that discounting the initial screen, when most late stage cancers were detected, would be more representative of a real-life steady state screening program.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731515</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731515-asco-2026-grail-shifts-focus-to-secondary-endpoints-in-uk-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Grail-Galleri-multicancer-early-detection-test-2-20.webp?t=1771619968" type="image/jpeg" medium="image" fileSize="215805">
        <media:title type="plain">Grail Galleri multicancer early detection test </media:title>
        <media:description type="plain">Credit: Grail Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Policy, aka politics, to have bigger role in US grants? </title>
      <description>
        <![CDATA[The Trump administration’s efforts to ensure U.S. federal grants align with its policies may soon be coming to fruition. The White House Office of Management and Budget released a proposed rulemaking to revise its Guidance for Federal Financial Assistance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731514</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731514-policy-aka-politics-to-have-bigger-role-in-us-grants</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-dollar-sign-and-gray-question-marks.webp?t=1729888911" type="image/jpeg" medium="image" fileSize="86003">
        <media:title type="plain">Gold dollar sign and gray question marks</media:title>
      </media:content>
    </item>
    <item>
      <title>Edgewise sells muscular dystrophy assets to Servier for $2.65B</title>
      <description>
        <![CDATA[Edgewise Therapeutics Inc. is pulling in $1.55 billion up front by selling its muscular dystrophy business, including its fast skeletal myosin inhibitor, sevasemten (EDG-5506), to Servier SA. The deal is potentially worth up to $2.65 billion when including a potential $1.1 billion in milestone payments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731512</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731512-edgewise-sells-muscular-dystrophy-assets-to-servier-for-265b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Purple-pie-chart.webp?t=1706041689" type="image/jpeg" medium="image" fileSize="65416">
        <media:title type="plain">Purple pie chart </media:title>
      </media:content>
    </item>
    <item>
      <title>Phase II bid Turns out safe, EASI, effective; AD topical island?</title>
      <description>
        <![CDATA[Turn Therapeutics Inc. made public strongly positive findings from an interim analysis that involves the first 50 subjects in the ongoing phase II atopic dermatitis (AD) trial with IL-36 inhibitor GX-03.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731511</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731511-phase-ii-bid-turns-out-safe-easi-effective-ad-topical-island</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Hand-holding-elbow.webp?t=1686261133" type="image/jpeg" medium="image" fileSize="145830">
        <media:title type="plain">Hand holding elbow</media:title>
      </media:content>
    </item>
    <item>
      <title>Oculis shifts focus after phase III DME disappointment</title>
      <description>
        <![CDATA[The much-awaited phase III readout from Oculis Holding AG’s OCS-01 in diabetic macular edema (DME) fell short of expectations, delaying the possibility of a topical eye drop option for DME patients and prompting the company to shuffle its pipeline priorities, with a focus on late-stage programs targeting optic neuropathies and dry eye disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731510</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731510-oculis-shifts-focus-after-phase-iii-dme-disappointment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eyedrops.webp?t=1620150844" type="image/png" medium="image" fileSize="518130">
        <media:title type="plain">Woman using eyedrops</media:title>
      </media:content>
    </item>
    <item>
      <title>Hanmi, Haisco win billion-dollar partnerships with Eli Lilly</title>
      <description>
        <![CDATA[Hanmi Pharmaceutical Co. Ltd. secured a $1.26 billion deal with Eli Lilly and Co. to out-license ex-Korea rights to sonefpeglutide (HM-15912), a Lapscovery-based glucagon-like peptide-2 analog in development for multiple indications, including an ongoing phase II study of short bowel syndrome. It was one of two billion-dollar Asian company deals signed by Lilly on June 1, with the second transaction involving Haisco Pharmaceutical Group Co. Ltd., of Beijing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731459</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731459-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Hanmi-signage-6-1.webp?t=1780342948" type="image/jpeg" medium="image" fileSize="195343">
        <media:title type="plain">Hanmi signage</media:title>
        <media:description type="plain">Credit: Hanmi Pharmaceutical Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal</title>
      <description>
        <![CDATA[Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731458</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731458-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Antibodies-attacking-cancer-cell.webp?t=1621365766" type="image/png" medium="image" fileSize="566115">
        <media:title type="plain">Antibodies attacking cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>China launches long-awaited drug data protection rules </title>
      <description>
        <![CDATA[China’s National Medical Products Administration has issued final implementation measures for drug trial data protection that mark a significant step toward aligning China’s pharmaceutical intellectual property framework with global standards.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731457</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731457-china-launches-long-awaited-drug-data-protection-rules</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cybersecurity-data-lock.webp?t=1588286982" type="image/png" medium="image" fileSize="321597">
        <media:title type="plain">Cybersecurity data lock</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS’ mezigdomide doubles PFS in multiple myeloma</title>
      <description>
        <![CDATA[Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma was successful. Nearly three months later, the magnitude of success for its Pomalyst (pomalidomide) successor is clear.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731454</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731454-bms-mezigdomide-doubles-pfs-in-multiple-myeloma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Multiple-myeloma---healthy-and-cancerous-bone-marrow.webp?t=1780089558" type="image/jpeg" medium="image" fileSize="209895">
        <media:title type="plain">Healthy (left) vs. cancerous bone marrow</media:title>
      </media:content>
    </item>
    <item>
      <title>Replimune tries again with melanoma drug post FDA shakeup</title>
      <description>
        <![CDATA[Industry watchers will be tracking closely Replimune Group Inc.’s latest attempt to secure U.S. FDA approval of its advanced melanoma candidate, RP-1 (vusolimogene oderparepvec). The company announced Friday it had reached alignment for resubmitting the twice-rejected BLA with the agency, which it said has pledged to prioritize the review.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731453</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731453-replimune-tries-again-with-melanoma-drug-post-fda-shakeup</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-exam2.webp?t=1636753413" type="image/png" medium="image" fileSize="424293">
        <media:title type="plain">Skin exam</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS-Hengrui deal strikes panic in Washington</title>
      <description>
        <![CDATA[On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731574</guid>
      <pubDate>Fri, 29 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731574-bms-hengrui-deal-strikes-panic-in-washington</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>TROP2 ADCs progress into first-line for lung, breast cancers</title>
      <description>
        <![CDATA[Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731648</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731648-trop2-adcs-progress-into-first-line-for-lung-breast-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Floating-antibody-drug-conjugates.webp?t=1737562655" type="image/jpeg" medium="image" fileSize="131818">
        <media:title type="plain">Floating antibody drug conjugates</media:title>
      </media:content>
    </item>
    <item>
      <title>TROP2 ADCs progress into first-line for lung, breast cancers</title>
      <description>
        <![CDATA[Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731444</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731444-trop2-adcs-progress-into-first-line-for-lung-breast-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Floating-antibody-drug-conjugates.webp?t=1737562655" type="image/jpeg" medium="image" fileSize="131818">
        <media:title type="plain">Floating antibody drug conjugates</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA’s VRBPAC faces complex COVID-19 landscape </title>
      <description>
        <![CDATA[Landing on the right COVID-19 vaccine formulation for the coming season is becoming more complicated against a backdrop of low vaccination rates, young children with little to no immunization, declining surveillance data and a new SARS-COV-2 lineage slowly emerging.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731442</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731442-fdas-vrbpac-faces-complex-covid-19-landscape</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/COVID-19-vaccine-vials-on-conveyor-belt.webp?t=1619033322" type="image/png" medium="image" fileSize="560497">
        <media:title type="plain">COVID-19 vaccine vials on conveyor belt</media:title>
      </media:content>
    </item>
    <item>
      <title>Elzonris this: FDA clears Abbvie’s Decnupaz in BPDCN</title>
      <description>
        <![CDATA[Payoff for the November 2023 buyout of Immunogen Inc. came for Abbvie Inc. in the form of U.S. FDA clearance for the CD123-targeting antibody-drug conjugate Decnupaz (pivekimab sunirine) to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare, aggressive and quick-killing hematologic malignancy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731440</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731440-elzonris-this-fda-clears-abbvies-decnupaz-in-bpdcn</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Blood-cancer-illustration.webp?t=1650579705" type="image/png" medium="image" fileSize="628557">
        <media:title type="plain">Blood cells and destruction of cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections</title>
      <description>
        <![CDATA[GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense oligonucleotide bepirovirsen.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731439</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731439-breakthrough-as-gsks-bepirovirsen-clears-19-of-chronic-hep-b-infections</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Liver-with-hepatitis-viruses.webp?t=1779996120" type="image/jpeg" medium="image" fileSize="162084">
        <media:title type="plain">Liver with hepatitis viruses, blood cells</media:title>
      </media:content>
    </item>
    <item>
      <title>D&amp;D’s zabopegdutide shows more upbeat top-line phase II MASH data </title>
      <description>
        <![CDATA[D&D Pharmatech Inc. announced May 27 positive top-line tissue biopsy results of zabopegdutide (DD-01) from a 48-week phase II study of metabolic dysfunction-associated steatohepatitis (MASH), pushing company shares up 30% on the day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731423</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731423-d-and-ds-zabopegdutide-shows-more-upbeat-top-line-phase-ii-mash-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-damage-fibrosis-cirrhosis.webp?t=1769528466" type="image/jpeg" medium="image" fileSize="677639">
        <media:title type="plain">Art concept for liver damage, such as fatty liver, fibrosis or cirrhosis</media:title>
      </media:content>
    </item>
  </channel>
</rss>
